ClinicalTrials.gg

Program

benserazide, levodopa drug combination

Also written as “HRG2010 Capsule, Sinemet®, Madopar®”, “Madopar® 250” and “levodopa/benserazide”.

Its studies are mostly in Parkinson Disease, led by 2 companies.

Furthest: phase 1, since Jan 24, 20123 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bial - Portela C20 open or runningphase 1since Jan 24, 2012Jan 24, 2012none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since May 9, 2025May 9, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2012First study: phase 1 study in Parkinson DiseaseNew to Bial - Portela CBial - Portela C · NCT01533116 · 52 enrolled · Canada
  2. Mar 27, 2017Phase 1 study in Parkinson DiseaseBial - Portela C · NCT03097211 · 38 enrolled · Portugal
  3. May 9, 2025Jiangsu HengRui Medicine’s first study: phase 1 study in Parkinson DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06976346 · 16 enrolled · China

TargetBeta

DDC →read by rule
“An orally available combination of benserazide, an aromatic L-amino acid decarboxylase (AADC) inhibitor, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties”NCIt, by rule

Other programs on DDC

ProgramCompanyFurthest phaseStudies
CarbidoparuleNovartisphase 425

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06976346Parkinson Disease · China1CompletedJiangsu HengRui MedicineOct 7, 202116
NCT03097211Parkinson Disease · Portugal1CompletedBial - Portela COct 20, 200638
NCT01533116Parkinson Disease · Canada1CompletedBial - Portela CAug 200952

How it is read

Names in the registry

  • “HRG2010 Capsule, Sinemet®, Madopar®”, 1 entry
  • “Madopar® 250”, 1 entry
  • “levodopa/benserazide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.